These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 6812144)

  • 1. Serotonin precursor effects in tardive dyskinesia.
    Nasrallah HA; Smith RE; Dunner FJ; McCalley-Whitters M
    Psychopharmacology (Berl); 1982; 77(3):234-5. PubMed ID: 6812144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
    Van Woert MH; Rosenbaum D; Howieson J; Bowers MB
    N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management.
    Nasrallah HA; Dunner FJ; McCalley-Whitters M; Smith RE
    J Clin Psychiatry; 1986 Feb; 47(2):56-9. PubMed ID: 3003037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
    Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD
    Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of tardive dyskinesia with lecithin.
    Jackson IV; Nuttall EA; Ibe IO; Perez-Cruet J
    Am J Psychiatry; 1979 Nov; 136(11):1458-60. PubMed ID: 40440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia.
    Suddath RL; Straw GM; Freed WJ; Bigelow LB; Kirch DG; Wyatt RJ
    Pharmacol Biochem Behav; 1991 Jul; 39(3):743-5. PubMed ID: 1686106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effects of L-5-hydroxytryptophan administration in chronic schizophrenic patients.
    Bigelow LB; Walls P; Gillin JC; Wyatt RJ
    Biol Psychiatry; 1979 Feb; 14(1):53-67. PubMed ID: 369623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
    Lerner V; Miodownik C; Kaptsan A; Cohen H; Matar M; Loewenthal U; Kotler M
    Am J Psychiatry; 2001 Sep; 158(9):1511-4. PubMed ID: 11532741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin and myoclonus.
    Van Woert MH; Jutkowitz R; Rosenbaum D; Bowers MB
    Monogr Neural Sci; 1976; 3():71-80. PubMed ID: 790170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study.
    de Montigny C; Chouinard G; Annable L
    Psychopharmacology (Berl); 1979 Nov; 65(3):219-23. PubMed ID: 117492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
    Van Woert MH; Sethy VH
    Neurology; 1975 Feb; 25(2):135-40. PubMed ID: 1078720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-tryptophan in neuroleptic-induced tardive dyskinesia.
    Sandyk R; Bamford CR; Khan I; Fisher H
    Int J Neurosci; 1988 Sep; 42(1-2):127-30. PubMed ID: 2905343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyproheptadine in levodopa-induced dyskinesia in parkinsonism.
    Papavasilliou PS; Cotzias GC; McDowell FH; Rosal VL; Sheehan PJ
    Clin Pharmacol Ther; 1978 Feb; 23(2):195-8. PubMed ID: 620480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
    Sternberg EM; Van Woert MH; Young SN; Magnussen I; Baker H; Gauthier S; Osterland CK
    N Engl J Med; 1980 Oct; 303(14):782-7. PubMed ID: 6997735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study.
    Jus A; Villeneuve A; Gautier J; Jus K; Villeneuve C; Pires P; Villeneuve R
    Neuropsychobiology; 1978; 4(3):140-9. PubMed ID: 340975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia].
    Karniol IG; Giampietro AC; Moura DS; Vilela WA; Oliveira MA; Zuardi AW
    Acta Psiquiatr Psicol Am Lat; 1983 Dec; 29(4):261-6. PubMed ID: 6369888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders.
    Stahl SM; Thornton JE; Simpson ML; Berger PA; Napoliello MJ
    Biol Psychiatry; 1985 Aug; 20(8):888-93. PubMed ID: 3861199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.